DRAPER, Utah, Nov. 15, 2022 (GLOBE NEWSWIRE) — HealthEquity, Inc. (NASDAQ:HQY) ("HealthEquity" or the "Company"), the nation’s largest health savings account ("HSA") custodian, today announced plans to release its. DRAPER, Utah, Nov. 15, 2022 (GLOBE NEWSWIRE) — HealthEquity, Inc. (NASDAQ: HQY) (“HealthEquity” or the “Company”), the nation’s largest health savings.

Philips’ Q3 performance impacted by operational and supply challenges; company is taking immediate actions to restore performance.DRAPER, Utah, Aug. 09, 2022 (GLOBE NEWSWIRE) — HealthEquity, Inc. (NASDAQ: HQY) (“HealthEquity” or the “Company”), the nation’s largest independent health savings account (“HSA”) non-bank custodian, today announced plans to release its second quarter of fiscal 2023 financial results following the close of regular stock market trading hours on Tuesday, September 6, 2022. Following the news release, HealthEquity management plans to host a conference call for investors on Tuesday, September 6, 202. Sun Life Financial Inc. (“SLF Inc.”), its subsidiaries and, where applicable, its joint ventures and associates are collectively referred to as “the Company”,. Myomo, Inc. (NYSE:NYSE:MYO) Q3 2022 Earnings Conference Call November 10, 2022 4:30 AM ET Company Participants Kim Golodetz – Investor Relations, LHA Paul Gudonis – Chief Executive Officer.

. .

Presentation Operator MessageOperator Welcome to the Myomo Inc. Third Quarter 2022 Earnings Conference Call. [Operator Instructions] Please note, this event is being recorded. I would now like to turn. | November 15, 2022. . CorMedix Inc. (NASDAQ:NASDAQ:CRMD) Q3 2022 Earnings Conference Call November 10, 2022 8:30 am ET Company Participants Joe Todisco – Chief Executive Officer Matt David – Executive Vice.

. Sun Life Financial, Inc. (NYSE:NYSE:SLF) Q3 2022 Earnings Conference Call November 03, 2022, 10:00 ET Company Participants Yaniv Bitton – VP, Head of IR & Capital Markets Kevin Strain -.

. Gilead Granted Exclusive Option to License MGD024, a Phase 1 CD123×CD3 DART ® Molecule with Potential to Treat Various Hematologic Malignancies – – Potential for Companies to Collaborate on Two Additional Future Research Programs – Gilead Sciences, Inc. and MacroGenics today announced an exclusive option and collaboration agreement to develop MGD024, an investigational, bispecific antibody that binds CD123 . .

. Philips provides update on its financial performance in Q3 2022. Presenter SpeechUnknown Analyst Thanks, everyone, for coming today, the last at Credit Suisse Healthcare Conference. With us today is Clover Health. And we have Vivek Garipalli, the current CEO, also. | November 15, 2022.

. Philips delivers Q1 sales of EUR 3.9 billion, with good demand driving 5% comparable order intake growth.Philips’ performance impacted by headwinds; order book strength and improving component supplies expected to deliver growth and profitability improvement from second half of 2022 onwards.